Guggenheim Capital LLC Vanda Pharmaceuticals Inc. Transaction History

Guggenheim Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$6.87 - $10.96 $27,005 - $43,083	-3,931 Reduced 9.14%	39,097 $288,000
Q3 2022 Nov 14, 2022	SELL	$9.44 - $11.76 $80,872 - $100,747	-8,567 Reduced 16.6%	43,028 $425,000
Q2 2022 Aug 15, 2022	BUY	$9.31 - $11.84 $26,002 - $33,069	2,793 Added 5.72%	51,595 $563,000
Q1 2022 May 16, 2022	BUY	$10.84 - $16.55 $71,348 - $108,932	6,582 Added 15.59%	48,802 $552,000
Q4 2021 Feb 14, 2022	SELL	$15.69 - $21.14 $184,498 - $248,585	-11,759 Reduced 21.78%	42,220 $662,000
Q3 2021 Nov 15, 2021	BUY	$15.35 - $21.27 $486,472 - $674,088	31,692 Added 142.2%	53,979 $925,000
Q2 2021 Aug 13, 2021	BUY	$15.71 - $21.51 $350,128 - $479,393	22,287 New	22,287 $479,000

155

43.7M

33.8K

28.7K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $270M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.